Search Results for: Clinical Roundup
- « first
- ‹ previous
- 1
- 2
- 3
-
European Report: New Biotech Products Should Rise In Future
The draft guideline urged a case-by-case approach for the nonclinical/clinical data package, dependent on the state of the art of analytical procedures, the manufacturing processes employed, and clinical and regulatory experience...It has been created to standardize the approach to early clinical use of valuable medicines in developmentBy Peter O'Donnell | BioWorld International | Wednesday, December 15, 2004 -
New Orphan Drug Guidance Disappoints Small EU Firms
It also had requested additional guidance on the types of preclinical or clinical data that could be considered as sufficient justification for the designation, with specific examples of diseases...Our sector has suffered too much from food scandals in the past to risk going against consumer opinion."By Peter O'Donnell | BioWorld International | Wednesday, September 8, 2004 -
EuropaBio Probes Fairness To Biotech In New EU Rules
Such agreements are the life-blood of the biotech industry, since few biotech companies have the resources to undertake late-stage clinical trials and so are reliant on out-licensing to big pharma partners to see their products through to market," it said...The website also groups the individual voting patterns by nation, showing that members of parliament from Austria, Belgium, Denmark, Finland, France, Greece, Ireland, the Netherlands, Portugal, Sweden and Spain were largely in favor of tighterBy Peter O'Donnell | BioWorld International | Wednesday, April 14, 2004 -
Hurdles For Europe Include Tissue Engineering, Patents
The biotech medicines sector will be further affected by new rules on clinical trials and pediatric medicines...If the dam breaks, the logjam of products could turn into a flood," one senior European executive told BioWorld International.By Peter O'Donnell | BioWorld International | Wednesday, February 11, 2004 -
EU Aiming To Pave Way For Tissue-Engineering Market
He recognizes that the small biotech companies involved do not have the resources for large, long-term clinical trials to provide information on the cost-effectiveness of the treatment compared to conventional alternatives...One of the items on the agenda will be whether the EU should authorize BT11 corn - the latest challenger to the five-year-old informal EU moratorium on GM approvals.By Peter O'Donnell | BioWorld International | Wednesday, January 28, 2004 -
Belgians Call On Europeans To Take Lead In Industrial Biotech
And while "the empirical and clinical approach continues to play a determining role" in life sciences research, "we know, too, that further progress can be expected in this area from work often of a very basic nature in the field of genomics and the neurosciences...The commission decided only to reconsider the matter at a further meeting on Jan. 28 - and it is still unclear whether the commission will be able to break the deadlock imposed by EU member states in 1999 on any new authorizationsBy Peter O'Donnell | BioWorld International | Wednesday, January 21, 2004 -
Report Shows How EU Firms Trail Americans, Even In Europe
It would require manufacturers to demonstrate that changes do not make new nonclinical or clinical studies necessary...The industry and other interested parties have until May to respond.By Peter O'Donnell | BioWorld International | Wednesday, December 3, 2003 -
European Commission Reports Biotechnology Research Plans
The European Federation of Pharmaceutical Industries and Associations has been lobbying Parliament over recent days to ensure that generic biotech products are required to undergo preclinical testing and clinical trials to demonstrate safety and efficacy...If that creates competition among member states for the most effective fostering framework, so much the better."By Peter O'Donnell | BioWorld International | Wednesday, November 19, 2003 -
EU Ministers Reach Compromise On Regulatory Drug Framework
In particular, it has been discussing new information on insertional oncogenesis, based on the analysis of available nonclinical and clinical data following two serious adverse events reported in a gene therapy trial in France for the treatment of children affected by X-linked severe combined immunodeficiency...It concluded that testing of gonads for the presence or expression of vector sequence "does not give sufficient information as to whether the germline has been altered."By Peter O'Donnell | BioWorld International | Wednesday, June 4, 2003 -
European Drug Agency Develops 2-Year Program For Working Party
Highlights of the initiatives that are likely to have the most impact on firms developing biotechnology medicines in Europe include updates to the existing guidance on comparability of medicines containing biotechnology-derived proteins as drug substance (as well as contributing to meetings of the EU ad hoc group dealing with clinical and preclinical issues of comparability...In terms of gene therapy and cell therapy, the plans include further advice on the quality and the preclinical and clinicalBy Peter O'Donnell | BioWorld International | Wednesday, January 29, 2003 -
Report Says EU Biotech Trails U.S. Due To Lack Of Coordination
The report suggests that increased funding is only a part of the solution, and that more pluralism in funding sources, lower dependence on closed national systems, and higher integration of research with teaching, clinical research and medical practice should become priorities of a European research policy for biotechnology...Submissions are being invited from organizations or groups of organizations from the 15 EU member states and the 13 EU candidate countries, but entities from other countriesBy Peter ODonnell | BioWorld International | Wednesday, April 24, 2002 -
Biotechnology Company Deals With Other Biotechnology Companies
once active leads identified, Immunex will elect whether to continue preclinical development with ArQule or to exclusively license leads to ArQule for clinical and commercial development (in exchange for milestones and royaltiesState of the Industry Report | Thursday, January 3, 2002 -
1998's Biotech - Big Agribusiness Collaborations
s Agsome agrochemical delivery system (nanoencapsulation) to develop enhanced formulation of Roundup herbicide ND This agreement expands scope of the parties...initial focus is Roundup Ready alfalfa ND Letter of intent signed...development, evaluation and release of new NK brand alfalfa varieties with Roundup Ready trait ND ND (8/98) Gene Logic IncState of the Industry Report | Thursday, January 3, 2002 -
Dragon Pharma Eyes Raising $8M In Private Placement
ImClone Systems Inc., of New York, disclosed the early achievement of a clinical development milestone under its agreement with Merck KgaA, of Darmstadt, Germany...Terms of the proposed offering were not disclosed.BioWorld International | Wednesday, June 6, 2001 -
Theologian Raises Ethical Issues On Biotechnology To Euro-MPs
EU Clinical Trials Rules Formalized The EU rules on clinical trials for new medicines have at last been formalized - some four months after the EU institutions agreed on the final details...The final version of the directive, which lays down good clinical practice rules for conducting clinical trials on human subjects, and provides for an early start to most clinical trials, still insists in its final form that: "Written authorization shall be required before commencing clinical trials involvingBy Peter O'Donnell | BioWorld International | Wednesday, May 16, 2001 -
Clinical Trials Rules Formalized; Estonian Gene Effort Continues
BioWorld International Correspondent BRUSSELS, Belgium - The European Union rules on clinical trials for new medicines - with their additional constraints on biotechnology products - have at last been formalized, some four months after European Union ministers and parliamentarians agreed on the final details...The results of the conference will be presented to the G-8 Summit of Heads of State and Government in Genoa, Italy, in July to support their discussions on biotechnology, and will feed intoBy Peter O'Donnell | BioWorld International | Wednesday, May 9, 2001 -
European Orphan Drugs Initiative Generates Applications, Support
Ultimately, it said, potential risk must be evaluated against the intended clinical use of products...Frenchman Philippe Brunet remains as head of unit for the regulatory framework and market authorizations for pharmaceuticals, and Abraao Carvalho of Portugal has been made head of a new unit responsible for biotechnology and competitiveness in pharmaceuticals.By Peter O'Donnell | BioWorld International | Wednesday, March 28, 2001 -
EU Ministers Give Final Approval To Rules Governing Clinical Trials
BioWorld International Correspondent BRUSSELS, Belgium - The European Union's new rules on clinical trials received their final approval, after more than a decade of discussion, from European ministers last week...This new directive aims to rationalize the documentation and administrative procedures for clinical trials on medicines, and at the same time to guarantee the same level of protection for patients across the EU...Until now, EU standards on good clinical practice were expressed only asBy Peter O'Donnell | BioWorld International | Wednesday, March 7, 2001 -
Biotech Collaborations In Agriculture: November 1998 April 1999
Roundup Ready alfalfa varieties for marketing by ABTBioWorld Insight | Monday, May 3, 1999
- « first
- ‹ previous
- 1
- 2
- 3
Category
Current Filters
- xNOT BioWorld Today
Related Keywords
Categories
- x BioWorld International (51)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.